Natco Pharma Ltd. — Capital/Financing Update 2019

Aug 28, 2019

Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax : +9140 23548243 CIN: L24230TG1981PLC003201 , www.natcophanna.co.in

August 23, 2019

To, Manager - Listing National Stock Exchange of India Ltd "Exchange Plaza", Bandra-Kurla Complex Bandra (E) Mumbai 400 051 .

Scrip Code: NA TCOPHARM

Dear Sir/Madam,

Sub: Clarification -NATCOPHARM - Reg. Ref: Email received on August 22, 2019

With reference to the email received on August 22, 2019 and also with reference to the outcome of Board Meeting held on August 9 2019, please find attached herewith the disclosure under Regulation 30 and sub-para (1) of para (A) of Part (A) of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed herewith.

This is for your information and record.

Thanking you,

Yours faithfull y, ForNATCO Pharma Limited

Mv'lill....ft..~ c.-t. ~

M. Adinarayana Company Secretary & Vice President (Legal & Corp. Affairs)

Encl: as above

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

SI.No.	Particulars	Details of Investment
A	Name of the target entity, details inbrief such as size, turnover etc.	1) Name of the target entityOMRV Hospitals Private Limited2) Details in brief such as size, turnoveretc.OMRV Hospitals Pvt Ltd is engaged in therunning of a hospital by the brand name"Pace Hospital" in Hyderabad, Telangana.In FY 2017-18, the revenue was INR 25.04crores.
B	Whether the acquisition would fallwithin related party transaction(s)and whether the promoter/ promotergroup/ group companies have anyinterest in the entity being acquired?If yes, nature of interest and detailsthereof and whether the same is doneat "arm's length"	No
c	Industry to which the entity beingacquired belongs	Health Care (Hospitals and Clinic)
D	Objects and effects of acquisition(includingbutnotlimitedto,disclosure of reasons for acquisitionof target entity, if its business isoutside the main line of business ofthe listed entity)	To support entrepreneurship and developmentof viable healthcare in Hyderabad
E	B1ief details of any governmental orregulatory approvals required for theacquisition	Not applicable
F	Indicativetimeperiodforcompletion of the acquisition;	September 30, 2019
G	Nature of consideration -whethercash consideration or share swapand details of the same	Convertible5,00,0000.05%CompulsoryCumulative Preference Shares (CCCPS) ofRs. l 00/-each
H	Cost of acquisition or the price atwhich the shares are acquired	Rs.5,00,00,000 (Rupees Five Crores only)
I	Percentage of shareholding I controlacquired and I or number of sharesacquired	Increase from the present 9.29% to 12.81 % ofthe shares on a fully diluted basis of OMRVHospitals Private Limited

1) OMRV Hospitals Private Limited

SI.No.	Particulars	Details of Investment
$\bf J$	brief background about the entityacquired in terms of products/line ofbusinessacquired,dateofincorporation, history of last 3 yearsturnover, country in which theacquired entity has presence and anyother significant information (inbrief)	1. Brief background:OMRV Hospitals Pvt Ltd is engaged in therunning and administration of hospital &clinic. Currently, it's operatingonehospital in Hyderabad.2. Line of business:
		Health Care (Hospitals and Clinic)3. Date of incorporation:23 rd September, 2011
		4. Turnover of last 3 years (in Rupees):For the FY 2017-18: 25,04,21,376For the FY 2016-17: 17,03,94,195For the FY 2015-16: 14, 14, 45, 6275. Country in which the acquired entityhas presence:
		India

$M_{\text{t}}$

$\lambda$

2) AACT, lac. (AACT)

SI.No.	Particulars	Details of Investment
A	Name of the target entity, details inbrief such as size, turnover etc.	1) Name of the target entityAACT, Inc. (AACT), USA2) Details in brief such as size, turnoveretc.
B	Whether the acquisition would fallwithin related party transaction(s)and whether the promoter/ promotergroup/ group companies have anyinterest in the entity being acquired?If yes, nature of interest and detailsthereof and whether the same is doneat "arm's length"	It is the first year of operation.No
c	Industry to which the entity beingacquired belongs	Pharmaceutical Research
D	Objects and effects of acquisition(includingbutnotlimitedto,disclosure of reasons for acquisitionof target entity, if its business isoutside the main line of business ofthe listed entity)	ofTosupportR&Danddevelopmentoncological products
E	Brief details of any governmental orregulatory approvals required for theacquisition	Reserve Bank of India
F	Indicativetimeperiodforcompletion of the acquisition;	March 31, 2020
G	Nature of consideration -whethercash consideration or share swapand details of the same	Around 250 Common stock of $0.001
H	Cost of acquisition or the price atwhich the shares are acquired	An amount around US$ 250,000 (US DollarsTwo hundred Fifty Thousand only)
[	Percentage of shareholding I controlacquired and I or number of sharesacquired	Around 6.25% of the shares on a fully dilutedbasis of AACT, Inc.

SI.No.	Particulars	Details of Investment
$\mathbf{J}$	brief background about the entityacquired in terms of products/line ofacquired, datebusinessofincorporation, history of last 3 yearsturnover, country in which theacquired entity has presence and anyother significant information (inbrief)	1. Brief background:AACT has identified certain proprietaryincludingbiotechnologycertainpre-clinical pharmaceutical compound(s)and wishes to conduct the pre-clinicaldevelopment of these drugs.2. Line of business:Pharmaceutical Research3. Date of incorporation:November 8, 20184. Turnover of last 3 years:Nil5. Country in which the acquired entityhas presence:USA

$\mu$ An

$\mathcal{A}_2$

$\langle \hat{\mathbf{e}} \rangle$